These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Leithead JA; Hayes PC; Ferguson JW Aliment Pharmacol Ther; 2014 Apr; 39(7):699-711. PubMed ID: 24528130 [TBL] [Abstract][Full Text] [Related]
7. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. Testro AG; Angus PW J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956 [No Abstract] [Full Text] [Related]
8. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. Arroyo V; Terra C; Ginès P J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801 [No Abstract] [Full Text] [Related]
9. Management of portopulmonary hypertension: new perspectives. Mancuso L; Scordato F; Pieri M; Valerio E; Mancuso A World J Gastroenterol; 2013 Dec; 19(45):8252-7. PubMed ID: 24363516 [TBL] [Abstract][Full Text] [Related]
13. [Pulmonary complications of hepatic cirrhosis: portopulmonary hypertension and hepatopulmonary syndrome. The paradox of pulmonary vasoconstriction and vasodilation]. Chávez-Tapia NC; Uribe M; López E Gac Med Mex; 2007; 143(4):333-9. PubMed ID: 17969842 [TBL] [Abstract][Full Text] [Related]
14. Novel use of sildenafil in the treatment of portopulmonary hypertension. Chua R; Keogh A; Miyashita M J Heart Lung Transplant; 2005 Apr; 24(4):498-500. PubMed ID: 15797756 [TBL] [Abstract][Full Text] [Related]